论文部分内容阅读
肿瘤发生是多种基因异常的共同结果,因而检测基因改变可用于肿瘤监测。约1/3急性髓细胞白血病(AML)可发生N-ras原癌基因点突变。随着简便、灵敏的半固相微测序法的建立,它将用于监测AML早期复发和定量检测残留白血病细胞;此外,髓细胞白血病患者降钙素基因高甲基化可作为判定疾病进展的分子标记,且特别有助于慢性髓细胞白血病(CML)分期。
Tumorigenesis is a common result of a variety of genetic abnormalities and therefore detection of genetic alterations can be used for tumor monitoring. Approximately one third of acute myeloid leukemias (AML) can undergo point mutations in the N-ras protooncogene. With the establishment of a simple and sensitive semi-solid micro-sequencing method, it will be used to monitor the early relapse and quantitative detection of residual leukemia cells in AML. In addition, the hypermethylation of calcitonin gene in myeloid leukemia may be used as a molecular marker for disease progression , And is particularly helpful for chronic myeloid leukemia (CML) staging.